-
Amazon's PillPack Acquisition: What It Means For The Tech Giant And Everybody Else
Friday, June 29, 2018 - 11:43am | 951Read More...Amazon.com, Inc. (NASDAQ: AMZN) announced its acquisition of PillPack, an online pharmacy previously targeted by Walmart Inc (NYSE: WMT). The transaction is seen to advance Amazon’s health care campaign to the detriment of the vast and diverse sector. What It Means For Amazon Amazon had...
-
Jefferies Downgrades Tenet As It Approaches Full Health
Friday, June 29, 2018 - 10:21am | 336Read More...Tenet Healthcare Corp (NYSE: THC) shares are up 128 percent year-to-date, reflecting cost-cutting efforts and earnings stabilization. But given the firm’s gains in top-line growth and multiple expansion, Jefferies expects the rally to come to an end. The Rating Analyst Brian...
-
Jefferies Downgrades Walgreens On Amazon's Competitive Threat
Friday, June 29, 2018 - 8:27am | 397Read More...Walgreens Boots Alliance Inc (NASDAQ: WBA) suffered a blow Thursday when Amazon.com, Inc. (NASDAQ: AMZN) announced its official foray into the pharmacy business. The retailer’s stock plunged on the news, and while Jefferies backed investor sentiment, it measured a higher Walgreens valuation...
-
What Wall Street Thinks Of The $69 Billion CVS-Aetna Deal
Monday, December 4, 2017 - 5:24pm | 1067Read More...Here we have it: the largest deal of 2017. CVS Health Corp (NYSE: CVS) confirmed Monday its agreement to acquire Aetna Inc (NYSE: AET) as a standalone business unit for about $207 per share. The parties intend to close the deal in the second half of 2018 to yield $750 million in near-term synergies...
-
Envision Healthcare Fundamentals Are 'Questionable,' Expect A Sell-Off
Wednesday, November 1, 2017 - 9:54am | 683Read More...Shares of Envision Healthcare Corporation (NYSE: EVHC) were trading notably lower by more than 30 percent Wednesday morning in reaction to the company's disappointing earnings report. Envision Healthcare cited the impact of hurricanes Harvey and Irma for its poor performance in the quarter, but...
-
Jefferies: Weakening Generic Drug Prices Putting Pressure On 3 Healthcare Stocks
Wednesday, May 17, 2017 - 2:12pm | 652Read More...Jefferies initiated coverage on Cardinal Health Inc (NYSE: CAH), AmerisourceBergen Corp. (NYSE: ABC) and McKesson Corporation (NYSE: MCK) Wednesday with Hold ratings. Jefferies’ analysis of prices paid by independent pharmacies for generic drugs leads analyst Brian Tanquilut to the conclusion...
-
Walgreens Volatility Is 'Noise'
Monday, January 23, 2017 - 9:19am | 357Read More...Jefferies’ Brian Tanquilut maintains a bullish stance on Walgreens Boots Alliance Inc (NASDAQ: WBA), stating that the stock volatility over the past week, driven by speculations regarding FTC concerns with the pending Rite Aid Corporation (NYSE: RAD) deal, is just near-term “noise....
-
CVS Health's Outlook For Next Year Hampered By 2 Factors
Monday, December 12, 2016 - 9:10am | 288Read More...While mentioning the pullback in CVS Health Corp (NYSE: CVS) shares in recent months, Jefferies’ Brian Tanquilut expressed concern regarding the stock’s outlook for the next 12 months. Tanquilut initiated coverage of the company with a Hold rating and price target of $82. Stock...
-
Why Walgreens Is A Buy, Regardless Of Rite-Aid Deal
Monday, October 17, 2016 - 10:25am | 396Read More...Walgreens Boots Alliance Inc (NASDAQ: WBA) and Rite Aid Corporation (NYSE: RAD) shareholders have been in limbo in recent months, as they wait to see whether the proposed merger of the two drugstore chains will be approved by regulators. Earlier this month, FTC commissioner Terrell McSweeny said...
-
Jefferies Bullish On Home Health; Points Out Positives For 19 Stocks
Friday, June 5, 2015 - 3:25pm | 969Read More...In a report published Friday morning, Jefferies analyst Brian Tanquilut and associate Jason Plagman provided some takeaways from the 2015 Jefferies Healthcare Conference. The analysts walked away with the sense that most companies were optimistic about "their near- and longer-term outlooks as...
-
Jefferies Downgrades Catamaran Amid News That Competing Bids For Company Are Unlikely
Tuesday, April 7, 2015 - 10:29am | 171Read More...Jefferies issued a company note on Tuesday highlighting Catamaran Corp (USA) (NASDAQ: CTRX). Jefferies downgraded Catamaran from Buy to Hold and raised its price target from $58 to $61.50. Analysts Brian Tanquilut and Jason Plagman wrote, "We expect the UnitedHealth Group Inc. (NYSE: UNH) offer to...
-
UPDATE: Jefferies Initiates Coverage on Envision Healthcare on Best Reform Play
Monday, September 23, 2013 - 10:03am | 112Read More...In a report published Monday, Jefferies analyst Brian Tanquilut initiated coverage on Envision Healthcare Holdings (NYSE: EVHC) with a Buy rating and $34.00 price target. In the report, Jefferies noted, “We are initiating coverage on EVHC with a Buy rating and a $34 PT based on our view that it is...
-
UPDATE: Jefferies Raises PT on Catamaran Corp. on Bullish Outlook
Thursday, August 8, 2013 - 9:17am | 113Read More...In a report published Thursday, Jefferies analyst Brian Tanquilut reiterated a Buy rating on Catamaran Corp. (NASDAQ: CTRX) and raised the price target from $65.00 to $70.00. In the report, Jefferies noted, “We have a bullish view on CTRX, especially now that all the overhangs on the name have...
-
UPDATE: Jefferies Raises PT on Health Management Associates on Continued Positive Outlook
Wednesday, July 10, 2013 - 8:44am | 129Read More...In a report published Wednesday, Jefferies analyst Brian Tanquilut reiterated a Buy rating on Health Management Associates (NYSE: HMA), and raised the price target from $14.50 to $20.00. In the report, Jefferies noted, “We continue to have a positive view on HMA shares despite the stock's...
-
UPDATE: Jefferies Raises PT on Mednax Following Recent Plateauing
Tuesday, May 28, 2013 - 9:17am | 111Read More...In a report published Tuesday, Jefferies analyst Brian Tanquilut reiterated a Buy rating on Mednax (NYSE: MD), and raised the price target from $95.00 to $108.00. In the report, Jefferies noted, “We continue to have a very positive bias on MD and view the stock's recent plateauing as a...
